ライフサイエンスコーパス: large-cell lymphoma

1 pression of CD30 (the hallmark of anaplastic large-cell lymphoma).

2 e for patients with CD30-positive anaplastic large cell lymphoma.

3 NS relapse or dissemination in patients with large cell lymphoma.

4 hronic lymphocytic leukemia (CLL) to diffuse large cell lymphoma.

5 ells of Hodgkin's lymphoma and by anaplastic large cell lymphoma.

6 hase 3 trial in recurrent/refractory diffuse large cell lymphoma.

7 ymphomatoid papulosis to systemic anaplastic large cell lymphoma.

8 e treatment of advanced cutaneous anaplastic large cell lymphoma.

9 eatment similar to that reported for diffuse large cell lymphoma.

10 iate- or high-grade lymphoma, 13 had diffuse large cell lymphoma.

11 equently translocated and mutated in diffuse large cell lymphoma.

12 bility to transform B lymphocytes in diffuse large cell lymphoma.

13 als in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.

14 ng classical Hodgkin lymphoma and anaplastic large cell lymphoma.

15 primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma.

16 ed in a patient with alk-positive anaplastic large-cell lymphoma.

17 prominently follicular lymphoma and diffuse large-cell lymphoma.

18 ic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma.

19 6 from lymphoblastic lymphoma, and five from large-cell lymphoma.

20 otherapy compared with other types of B-cell large-cell lymphoma.

21 factors for CNS recurrence in patients with large-cell lymphoma.

22 cell lymphoma and two ferrets had high-grade large-cell lymphoma.

23 ntial Ig sequence analysis in 1 patient with large-cell lymphoma.

24 atients with Hodgkin lymphoma and anaplastic large-cell lymphoma.

25 with refractory solid tumours and anaplastic large-cell lymphoma.

26 nd blood samples of patients with anaplastic large-cell lymphoma.

27 jected SCID mice developed aggressive murine large cell lymphomas.

28 istinguishing this disease from ALK-negative large cell lymphomas.

29 istics of primary patient-derived anaplastic large cell lymphomas.

30 matory myofibroblastic tumors and anaplastic large cell lymphomas.

31 n of follicular lymphomas to more aggressive large cell lymphomas.

32 ng Classical Hodgkin and systemic anaplastic large cell lymphomas.

33 indistinguishable from patients' anaplastic large cell lymphomas.

34 n gammaHV68-infected animals were B220+/CD3- large-cell lymphomas.

35 y represent the cell of origin of some human large-cell lymphomas.

36 indistinguishable from patients' anaplastic large-cell lymphomas.

37 characteristic of patient-derived anaplastic large-cell lymphomas.

38 ]), angiocentric lymphoma (4/4), a subset of large-cell lymphomas (10/21 [48%]), and lymphomas with a

39 Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not

40 ALK)-positive and 48 ALK-negative anaplastic large cell lymphoma, 14 adult T-cell leukemia/lymphoma a

41 Three patients had anaplastic large-cell lymphoma, 15 had mycosis fungoides or Sezary

42 non-Hodgkin lymphoma, except ALK+ anaplastic large cell lymphoma, 18 to 60 years, all stages, and all

43 oid granulomatosis), 12/19 T-cell anaplastic large-cell lymphomas, 2/12 nodal peripheral T-cell lymph

44 In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entities were CD

45 One patient with cutaneous anaplastic large cell lymphoma (8 mg/kg) achieved a complete respon

46 Patients who undergo transformation to large-cell lymphoma (8% to 23% of patients) have a poor

47 to 3% of patients per year into aggressive, large cell lymphoma, a critical event in the course of t

48 (8 out of 34) activated B cell-like diffuse large cell lymphoma (ABC-DLBCL), but not in GC B cell-li

49 of MALT lymphoma to activated B-cell diffuse large-cell lymphoma (ABC-DLBCL).

50 All seven patients without anaplastic large-cell lymphoma achieved CR.

51 ose expression is up-regulated on anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL) cel

52 the neoplastic transformation of anaplastic large cell lymphoma (ALCL) and the Reed-Sternberg cell o

53 contributes to the oncogenesis of anaplastic large cell lymphoma (ALCL) are not completely understood

54 uxotrophy, particularly in ALK(+) anaplastic large cell lymphoma (ALCL) cell lines and primary tumour

55 We used various ALK-positive anaplastic large cell lymphoma (ALCL) cell lines to evaluate two in

56 malignant lymphocytes, including anaplastic large cell lymphoma (ALCL) cells.

57 IP is frequently low or absent in anaplastic large cell lymphoma (ALCL) compared to other T cell lymp

58 ic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) constitutes an ideal model di

59 malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and are usually

60 ic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) frequently carries the t(2;5)

61 dies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound clinical suc

62 ority of LyP patients progress to anaplastic large cell lymphoma (ALCL) in which skin lesions no long

63 ic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a CD30-positive T-cell non

64 Anaplastic large cell lymphoma (ALCL) is a distinct clinicopatholog

65 Anaplastic large cell lymphoma (ALCL) is a distinct entity of T-cel

66 Anaplastic large cell lymphoma (ALCL) is a highly proliferative neo

67 Anaplastic large cell lymphoma (ALCL) is a mature T cell neoplasm t

68 Anaplastic large cell lymphoma (ALCL) is a mature T-cell lymphoma t

69 Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell lympho

70 Systemic anaplastic large cell lymphoma (ALCL) is an aggressive CD30(+) non-

71 Anaplastic large cell lymphoma (ALCL) is an aggressive non-Hodgkin

72 Systemic anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymph

73 Anaplastic large cell lymphoma (ALCL) is composed of large, frequen

74 Anaplastic large cell lymphoma (ALCL) is the most common type of pe

75 In the DHL cell line, an Anaplastic Large Cell Lymphoma (ALCL) line, a DNA rearrangement was

76 a subset of T-cell lymphomas with anaplastic large cell lymphoma (ALCL) morphology (ALK+ ALCL), the v

77 s detected in LyP lesions and the anaplastic large cell lymphoma (ALCL) of 2 patients and the mycosis

78 lymphoma kinase-positive (ALK(+)) anaplastic large cell lymphoma (ALCL) patients.

79 ly 30% of pediatric patients with anaplastic large cell lymphoma (ALCL) relapse.

80 In ALK-rearranged anaplastic large cell lymphoma (ALCL), a specific subtype of T-cell

81 Anaplastic large cell lymphoma (ALCL), an aggressive CD30-positive

82 sed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL), the single agent response ra

83 he biology and treatment of CD30+ anaplastic large cell lymphoma (ALCL), we transplanted leukemic tum

84 LK) are detected in 50% to 70% of anaplastic large cell lymphoma (ALCL), which is a T/null cell non-H

85 in (NPM)-ALK fusion protein in an anaplastic large cell lymphoma (ALCL)-derived cell line carrying th

86 sed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).

87 y efficacious in animal models of anaplastic large cell lymphoma (ALCL).

88 ic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).

89 ncluding Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL).

90 expressed in a subset of cases of anaplastic large cell lymphoma (ALCL).

91 expressed in a subset of systemic anaplastic large cell lymphoma (ALCL).

92 (ALK) consistent with a null cell anaplastic large cell lymphoma (ALCL).

93 n and malignant transformation of anaplastic large cell lymphoma (ALCL).

94 cells of Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL).

95 psed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL).

96 e poorly understood in ALK-driven anaplastic large cell lymphoma (ALCL).

97 ts with Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL).

98 netic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory myofibrobla

99 haracteristically translocated in Anaplastic Large Cell Lymphomas (ALCL) and the juxtaposition of the

100 The subset of CD30-positive anaplastic large cell lymphomas (ALCL) with the NPM-ALK gene fusion

101 nucleophosmin-ALK oncoprotein in anaplastic large cell lymphomas (ALCL).

102 (NSCLC) and approximately 70% of anaplastic large cell lymphomas (ALCL).

103 -derived neoplasias, most notably anaplastic large-cell lymphoma (ALCL) and Hodgkin's lymphoma.

104 herapy of certain cancers such as anaplastic large-cell lymphoma (ALCL) and inflammatory myofibroblas

105 ents in several tumors, including anaplastic large-cell lymphoma (ALCL) and non-small cell lung carci

106 homa kinase-positive (NPM-ALK(+)) anaplastic large-cell lymphoma (ALCL) as model system, we found in

107 s) are expressed in many cases of anaplastic large-cell lymphoma (ALCL) but are absent from normal ti

108 Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(2;5; p23;q3

109 , was specifically found in all 4 anaplastic large-cell lymphoma (ALCL) cell lines, but not in any of

110 Anaplastic large-cell lymphoma (ALCL) frequently carries the t(2;5)

111 % of patients with advanced-stage anaplastic large-cell lymphoma (ALCL) harbor the balanced chromosom

112 c proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) have been well defined; never

113 Anaplastic large-cell lymphoma (ALCL) is a clinical and biological

114 Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently described clini

115 Systemic anaplastic large-cell lymphoma (ALCL) is a T-cell lymphoma, whose a

116 Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive subtype of T

117 Primary CD30(Ki-1)-positive anaplastic large-cell lymphoma (ALCL) is considered by some to be a

118 on-Hodgkin lymphoma (NHL) subtype anaplastic large-cell lymphoma (ALCL) is frequently associated with

119 otein (Rb) in the pathogenesis of anaplastic large-cell lymphoma (ALCL) is unknown.

120 ficance of survivin expression in anaplastic large-cell lymphoma (ALCL) is unknown.

121 c proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) is well established.

122 Anaplastic large-cell lymphoma (ALCL) of T- or null-cell lineage, a

123 Anaplastic large-cell lymphoma (ALCL) provides an excellent example

124 Anaplastic large-cell lymphoma (ALCL) represents a heterogeneous gr

125 matologic malignancy ALK-positive anaplastic large-cell lymphoma (ALCL) resistant to ALK-specific tyr

126 regulated in T-lymphomas, such as anaplastic large-cell lymphoma (ALCL) tumors.

127 c lymphoma kinase (ALK) -positive anaplastic large-cell lymphoma (ALCL) was excluded.

128 Anaplastic large-cell lymphoma (ALCL) was initially recognized on t

129 lymphoma kinase-positive (ALK(+)) anaplastic large-cell lymphoma (ALCL), and adult T-cell leukemia/ly

130 dgkin's lymphoma (HL), three with anaplastic large-cell lymphoma (ALCL), and two with CD30+ T-cell ly

131 5) translocation, associated with anaplastic large-cell lymphoma (ALCL), results in the production of

132 In anaplastic large-cell lymphoma (ALCL), the (2;5) chromosomal transl

133 ts with Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), the study by Jacobsen and co

134 LK) in patients with ALK-positive anaplastic large-cell lymphoma (ALCL).

135 portant pathogenetic role in ALK+ anaplastic large-cell lymphoma (ALCL).

136 contribute to oncogenesis in ALK+ anaplastic large-cell lymphoma (ALCL).

137 losely represent a model of human anaplastic large-cell lymphoma (ALCL).

138 -3 in all of the 8 cases of Ki-1+ anaplastic large-cell lymphoma (ALCL).

139 ic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL).

140 an lymphoma (initially designated anaplastic large cell lymphoma [ALCL] or Ki-1/CD30-positive lymphom

141 7 Burkitt's lymphoma [BL], and 4 anaplastic large cell lymphoma [ALCL]), and 25 nonmalignant lymph n

142 astic T-cell lymphoma [AITL], and anaplastic large-cell lymphoma [ALCL]) is difficult, with the morph

143 ts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC).

144 Anaplastic large cell lymphomas (ALCLs) are caused by chromosomal t

145 The majority of pediatric anaplastic large cell lymphomas (ALCLs) carry the t(2;5)(p23;q35) c

146 Anaplastic Large Cell Lymphomas (ALCLs) carry translocations in whi

147 Anaplastic large cell lymphomas (ALCLs) frequently carry oncogenic

148 ion in lymphomas, with a focus on anaplastic large cell lymphomas (ALCLs), which are known to express

149 ccurring in approximately half of anaplastic large cell lymphomas (ALCLs).

150 event in the pathogenesis of most anaplastic large cell lymphomas (ALCLs).

151 aplastic lymphoma kinase (ALK)(-) anaplastic large cell lymphomas (ALCLs).

152 stic lymphoma kinase (ALK)- nodal anaplastic large cell lymphomas (ALCLs; n = 24) were obtained.

153 Anaplastic large-cell lymphomas (ALCLs) are a group of clinically a

154 cutaneous and primary nodal CD30+ anaplastic large-cell lymphomas (ALCLs) are distinct clinical entit

155 Anaplastic large-cell lymphomas (ALCLs) bearing the t(2;5) transloc

156 Anaplastic large-cell lymphomas (ALCLs) encompass at least 2 system

157 the survival and proliferation of anaplastic large-cell lymphomas (ALCLs).

158 ic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALK-negative), despite their unique

159 aplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK(+) ALCL) is a unique type of T-

160 iated with an improved outcome in anaplastic large-cell lymphoma, ALK positive.

161 contrast, the malignant cells in anaplastic large cell lymphoma and most high-grade tumors, includin

162 Virtually all diffuse large cell lymphomas and a significant fraction of folli

163 are among the most common lesions in diffuse large-cell lymphoma and have been associated with a poor

164 f the ALK tyrosine kinase gene in anaplastic large-cell lymphoma and inflammatory myofibroblastic tum

165 ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibroblastic tum

166 CD30 expression is universal in anaplastic large-cell lymphoma and is expressed in some other perip

167 y expressed in a subset of T-cell anaplastic large-cell lymphoma and non-small-cell lung cancer, resp

168 The BCL-6 gene is involved in diffuse large-cell lymphoma and overexpressed in other types of

169 /flow-positive cases were from patients with large-cell lymphomas and bulky clinical disease.

170 gh levels of BSAP, especially those found in large-cell lymphomas and in some follicular lymphomas, m

171 activated B-like from germinal-center B-like large-cell lymphomas and provide important pathobiologic

172 pression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive cytokine I

173 's transformation (CLL that has evolved into large-cell lymphoma) and only one case of CLL progressio

174 (14 large-B-cell lymphomas and 10 anaplastic large-cell lymphomas), and 15 highly aggressive lymphoma

175 apulosis (LyP), primary cutaneous anaplastic large cell lymphoma, and borderline cases.

176 angioimmunoblastic, ALK-negative anaplastic large cell lymphoma, and enteropathy-associated T-cell l

177 , respectively, for patients with anaplastic large-cell lymphoma, and 63.8% (SE, 10.3%) and 70.3% (SE

178 t otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma, and adult T-cell leukemia/lymphoma

179 e-cell immunoblastic lymphoma and anaplastic large-cell lymphoma, and all 12 cases studied lacked c-m

180 is (LyP), anaplastic and nonanaplastic CD30+ large-cell lymphoma, and borderline cases, comprise a cl

181 nsplantation in patients with diffuse B-cell large-cell lymphoma, and, specifically, to evaluate the

182 fuse large cell B-cell lymphomas, anaplastic large-cell lymphomas, and Epstein-Barr virus-induced B-c

183 amine T-cell lymphomas, including anaplastic large-cell lymphoma, angioimmunoblastic T-cell lymphoma,

184 Rare histologies include Ki-1 anaplastic large cell lymphoma, angiotropic large cell lymphoma, mu

185 Approximately 40% of diffuse large cell lymphoma are associated with chromosomal tran

186 phoma kinase (NPM-ALK) expressing anaplastic large cell lymphoma are not completely understood.

187 Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expre

188 mphomas of T or NK phenotype, and anaplastic large-cell lymphomas are cytotoxic T-or NK-cell neoplasm

189 and develop the morphologic appearance of a large cell lymphoma, are undefined.

190 B cell diffuse large cell lymphoma (B-DLCL) is a heterogeneous group of

191 ure-free survival (FFS) for PTCLs and B-cell large-cell lymphomas (BCLCLs) is 38% and 55%, respective

192 lved in breast implant-associated anaplastic large cell lymphoma (BI-ALCL) remain elusive.

193 rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) at a high-volume single i

194 Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a very rare type of T-

195 h rare, breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a CD30+ T-cell lymphoma

196 Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare peripheral T-cell

197 Breast implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is a CD30-positive, anapl

198 Breast-implant-associated anaplastic large-cell lymphoma (BIA-ALCL) is an uncommon, recently

199 of relapsed Hodgkin and systemic anaplastic large cell lymphomas--both characterized by high express

200 breaks and translocations in the anaplastic large cell lymphoma breakpoint regions of NPM1 and ALK.

201 Breast implant-associated anaplastic large cell lymphoma (breast implant ALCL) is an uncommon

202 of relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma by the Food and Drug Administration.

203 ree of 10 primary cutaneous CD30+ anaplastic large-cell lymphoma (C-ALCL).

204 of the Hodgkin's disease cases, eight of the large-cell lymphoma cases, and six of the lymphomatoid p

205 In anaplastic large cell lymphoma, CD30 triggering induces growth arre

206 to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malignant lympho

207 ase (ALK)-positive and -negative, anaplastic large cell lymphoma cell lines and primary patient tumou

208 plastic lymphoma kinase-positive, anaplastic large cell lymphoma cell lines and that ectopically expr

209 NPM/ALK-negative, patient-derived anaplastic large cell lymphoma cell lines.

210 set of acute myeloid leukemia and anaplastic large-cell lymphoma cell lines by inducing cell-cycle ar

211 rge B-cell lymphoma, ALK-positive anaplastic large cell lymphoma, chronic myelogenous leukemia, and a

212 morphologically more high grade (50% diffuse large cell lymphoma) compared with primary CL (37% low-g

213 In patients with diffuse large-cell lymphoma (DLBCL), we observed higher levels o

214 -cell lymphomas (DMxs), and 16 of 84 diffuse large-cell lymphomas (DLCCs); the difference between the

215 disease case (MAL) and KI-1 positive diffuse large cell lymphoma (DLCL) cell line (KIS-1).

216 of aberrant somatic hypermutation in diffuse large cell lymphoma (DLCL), the most common form of non-

217 data set based on 160 patients with diffuse large cell lymphoma (DLCL).

218 0.57; 0.34-0.94), particularly with diffuse large cell lymphoma (DLCL; OR = 0.29; 0.10-0.82).

219 In approximately 40% of diffuse large cell lymphomas (DLCL) and approximately 14% of fol

220 NHL and of two predominant subtypes, diffuse large-cell lymphoma (DLCL) (n = 233) and follicular lymp

221 eatures of 71 cases of primary CD30+ diffuse large-cell lymphomas (DLCL) and 128 cases of Hodgkin's d

222 ious other partners are recurrent in diffuse large-cell lymphomas (DLCL).

223 CPP32 was present in 10 of 12 (83%) diffuse large cell lymphomas (DLCLs) and 2 of 3 diffuse mixed B-

224 (ARHH) and PAX5, in more than 50% of diffuse large-cell lymphomas (DLCLs), which are tumours derived

225 showed morphologic transformation to diffuse large-cell lymphoma (DLL) in the second biopsy.

226 as (DSCCs), 2 of 17 diffuse mixed small- and large-cell lymphomas (DMxs), and 16 of 84 diffuse large-

227 2;5) translocation in a subset of anaplastic large cell lymphomas, encodes a Mr 75,000 hybrid protein

228 ed by the t(2;5) translocation in anaplastic large-cell lymphoma, encodes a M(r) 75,000 hybrid protei

229 l T-cell lymphomas--including one anaplastic large cell lymphoma--expressed CD95.

230 stologic classification revealed 21 cases of large cell lymphoma, five cases of lymphoblastic lymphom

231 It is debated whether follicular large cell lymphoma (FLCL) has a clinical behavior that

232 follicular mixed cells (FMs) and follicular large cell lymphomas (FLCLs) was strongly CPP32 immunopo

233 rge-cell lymphomas (FMxs), 1 of 4 follicular large-cell lymphomas (FLCs), 1 of 14 diffuse small cleav

234 f 35 follicular mixed small cleaved-cell and large-cell lymphomas (FMxs), 1 of 4 follicular large-cel

235 mechanism for escape of cutaneous anaplastic large cell lymphoma from tumor regression.

236 and ATLL and a lower incidence of anaplastic large-cell lymphoma; Hispanics had a higher incidence of

237 patients, particularly those with anaplastic large-cell lymphoma histology.

238 e molecular features of EBV-positive diffuse large cell lymphomas in 2 patients with RA.

239 t's lymphoma and Epstein-Barr-virus-negative large-cell lymphoma in AIDS patients, but not in immunos

240 , or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibroblastic tumour

241 e disorders, and that lymph node-based CD30+ large cell lymphoma is a disease that is biologically di

242 Breast implant-associated anaplastic large cell lymphoma is a rare cancer in patients with br

243 Anaplastic large-cell lymphoma is associated with a chromosomal tra

244 In T-cell lymphomas, anaplastic large-cell lymphoma is defined by mutually exclusive rea

245 pressed on Hodgkin's lymphoma and anaplastic large cell lymphoma, it is a promising target for immuno

246 interfering RNA transfection of T-anaplastic large cell lymphoma Karpas 299.

247 More than 60% of anaplastic large-cell lymphomas (Ki-1 lymphoma) are associated with

248 with newly diagnosed nonlocalized anaplastic large cell lymphoma kinase (ALK)+/CD30+ ALCL.

249 transcriptase-polymerase chain reaction), 1 large cell lymphoma (LCL) arising subsequent to MALT lym

250 ymphoma (NHL) subset commonly referred to as large cell lymphoma (LCL) has historically been characte

251 Large-cell lymphoma (LCL) arising in the mediastinum (LC

252 ients with small non-cleaved-cell (SNCL) and large-cell lymphoma (LCL) treated with intensive chemoth

253 ligible pediatric patients with stage III/IV large-cell lymphoma (LCL); 90 patients were randomly ass

254 the relationship to composite or sequential large-cell lymphomas (LCLs) is poorly understood.

255 target different receptors on the anaplastic large cell lymphoma line L-82, but delivered the same cy

256 RB is involved in differentiation, the U937 large-cell lymphoma line was induced to differentiate al

257 geneous histologic type of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small n

258 anaplastic large cell lymphoma, angiotropic large cell lymphoma, mucosa-associated lymphoid tissue,

259 as robust enough to differentiate anaplastic large cell lymphoma (n = 32) from other PTCLs.

260 a in patients with secondary CL were diffuse large cell lymphoma (n = 5, 28%), chronic lymphocytic le

261 T-cell lymphoma/leukemia (n = 4), anaplastic large-cell lymphoma (n = 2), and extranodal natural kill

262 Hodgkin's disease (twelve cases), and CD30+ large-cell lymphoma (nine cases) was tested for the HTLV

263 ubset included lines derived from anaplastic large cell lymphomas, non-small-cell lung cancers, and n

264 ympho-hematopoietic malignancies, anaplastic large cell lymphoma (NPM-ALK) and acute promyelocytic le

265 d with oral methotrexate (MTX) who developed large cell lymphoma of B cell phenotype.

266 apulosis, seven with primary cutaneous CD30+ large cell lymphoma of T-cell lineage, and five with Hod

267 apulosis (14 cases), primary cutaneous CD30+ large cell lymphoma of T-lineage (10 cases) and Hodgkin'

268 a high proportion of lymph node-based CD30+ large cell lymphomas of T-cell lineage.

269 ymphomas (37 of 40 cases) as well as diffuse large-cell lymphomas of B-cell type (35 cases) did not e

270 lymphoma and treated patients with advanced large-cell lymphoma on a separate protocol (doxorubicin,

271 K aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblastoma, three

272 In SCID mouse xenograft models of anaplastic large cell lymphoma or Hodgkin disease, cAC10-vcMMAE was

273 mphoma (P =.0005) and an increase in diffuse large cell lymphoma (P <.0001).

274 ation detected in the majority of anaplastic large cell lymphoma patients, and has recently been impl

275 16 relapsed CLL and 9 RT (all proven diffuse large cell lymphoma) patients were enrolled, and 60% rec

276 om 31 (34%) had a primary mediastinal B-cell large-cell lymphoma (PML).

277 valuable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy and for whom

278 actory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, relapsed or refractory B-cell precu

279 rhabdomyosarcoma, neuroblastoma, anaplastic large cell lymphoma, renal cell carcinoma, and inflammat

280 In patients with diffuse large-cell lymphoma, serum interleukin-6 levels are an i

281 NPM-ALK expression in mice causes B-lineage large-cell lymphoma, suggesting a direct causative role

282 For 21 patients with relapsed or refractory large cell lymphoma, the EFS rate was 81% and the OS rat

283 ymphoma and, in a subset of cases of diffuse large cell lymphoma, the mechanism of Bcl-6 overexpressi

284 vided clues toward the outcome of anaplastic large cell lymphoma; the breakpoints of t(2;5) were mapp

285 cases of the non-Hodgkin's lymphoma, diffuse large cell lymphoma, there are translocations of the BCL

286 aplastic lymphoma kinase-positive anaplastic large cell lymphoma), upfront auto-SCT was associated wi

287 We examined a series of marine RAW117 large cell lymphoma variants selected in vivo for liver-

288 oid papulosis and cutaneous CD30+ anaplastic large cell lymphoma was shown, suggesting that activatio

289 a randomized, prospective clinical trial in large cell lymphoma, we conducted serial fluorodeoxygluc

290 s fungoides (T-MF), and cutaneous anaplastic large cell lymphoma were studied in parallel with corres

291 licular small cleaved and five of 13 diffuse large cell lymphomas were KAI1 negative.

292 omas (targeting 75% with systemic anaplastic large cell lymphoma) were randomly assigned 1:1 to recei

293 2-like PTCL studied, all cases of anaplastic large cell lymphoma, were immunoreactive for LEF-1 or TC

294 is fungoides or primary cutaneous anaplastic large-cell lymphoma who had been previously treated.

295 118 untreated patients with diffuse large-cell lymphoma who were enrolled in frontline chemo

296 ease often transforms into a more aggressive large cell lymphoma with a rapidly progressive clinical

297 w-negative cases included 5 follicular and 5 large-cell lymphomas with minimal marrow involvement.

298 -ALK) is a key oncogenic event in anaplastic large-cell lymphomas with the characteristic chromosomal

299 ry syndrome, or primary cutaneous anaplastic large cell lymphoma, with disease progression after >/=

300 hematologic malignancies such as anaplastic large cell lymphoma, yet these mAb have not been efficac